ASCO 2026: Fezolinetant for Vasomotor Symptoms in Patients With Breast Cancer

Tier 2: Professional organization or credentialed expert guidance
Publisher: American Society of Clinical Oncology (Journal of Clinical Oncology) · Published: June 1, 2026 · Accessed: September 4, 2026

Visit the source ↗

Claims this source supports

• As of the 2026 ASCO Annual Meeting, fezolinetant (FDA-approved 2023 for menopausal vasomotor symptoms) had not been studied in breast cancer patients in a prospective trial; an observational survey-based study presented there reported feasibility and potential benefit for endocrine-therapy-associated vasomotor symptoms and called for prospective investigation.
• A phase 3 randomized placebo-controlled study of fezolinetant in women with stage 0-3 hormone receptor-positive breast cancer receiving adjuvant endocrine therapy was in progress (trial-in-progress abstract, JCO 2026).